艾易舒注射液联合动脉栓塞化疗治疗肝细胞性肝癌的临床观察  

Clinical observation of Aiyishu injection combined with TACE in the treatment of hepatocellular liver cancer

作　　者：张斌[1] 

机构地区：[1]上海长海医院,上海200433

出　　处：《中国医药导报》2007年第09Z期48-49,共2页China Medical Herald

摘　　要：目的:观察艾易舒在肝癌介入栓塞治疗中的作用。方法:100例肝癌随机分为艾易舒治疗组和对照组。两组均行THP+碘油方案的介入栓塞,治疗组在介入后行艾易舒治疗,每天50ml,连续4周。对照组不使用艾易舒治疗。介入后4周评价客观疗效、生活质量、症状改善率和毒副反应。结果:两组的近期客观疗效和毒副反应无明显差异,但生活质量治疗组明显高于对照组(P<0.05),症状改善率治疗组为74.51%,对照组为57.14%。结论:艾易舒注射液可提高肝癌患者介入后生活质量并改善症状。Objective： To observe effect and safety of Aiyishu injection combined with TACE （trans-arterial chemoembolization） in liver cancer.Methods： 100 liver cancer patients were divided into Aiyishu group and control group randomly. Both of them received THP plus iodine oil TACE. Aiyishu group received Aiyishu 50 ml iv daily continued 4 weeks. Objective effect, QOL（quality of life）, symptom improve rate and side-effect were evaluated after 4 weeks.Results： There were no obvious difference between two groups in objective effect and side-effect. But QOL in Aiyishu group was higher than control group （P〈0.05）. The symptom improve rate in Aiyishu group and control group was 74.51% and 57.14%.Conclusion： Aiyishu injection increase the QOL and symptom improve rate in liver cancer patients after TACE.

关 键 词：艾易舒注射液 动脉化疗栓塞 肝细胞性肝癌 

分 类 号：R735[医药卫生—肿瘤]